Shorter Treatment Succeeds in Septic Arthritis
Two weeks of antibiotic therapy was as effective as 4 weeks for septic arthritis, a prospective single-center study found.
News
Targeting GM-CSF Works in Rheumatoid Arthritis
Namilumab, a monoclonal antibody that targets the granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand, showed promise as a treatment for rheumatoid arthritis (RA) in a phase II study.
RheumNow Podcast – Take it Back Jack! (4.26.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Naproxen has no Effect on Alzheimer's
A randomized controlled trial shows that chronic low-dose naproxen does not reduce progression of presymptomatic Alzheimer disease (AD).
More Studies Needed to Optimize the Use of Osteoporosis Drugs
The Annals of Internal Medicine reports a metanalysis done to examine the optimal length of long-term osteoporosis drug treatment (ODT) and whether harms are associated with long-term ODT and while the ODT benefits are clear, the risk of rare harms and need for drug holidays is less certain. 
Skyrizi (risankizumab) FDA Approved for Psoriasis
AbbVie has announced that the US FDA has granted the approval of Skyrizi (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis.
Ustekinumab Effective in Behcet's Disease
A small prospective study has shown that ustekinumab is safe and effective in Behçet's disease (BD) with recurrent oral ulcers (OU).
NIH Workshop on Unmet Needs in Osteoporosis
In October 2018, the National Institutes of Health (NIH) convened a workshop to address the "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention"
Improved Survival in Lupus
A longitudinal study of systemic lupus erythematosus (SLE) from the Toronto Lupus Clinic has shown that mortality has decreased over time.
Statins in RA Patients Without CVD: Nonsignificant Results
Patients with RA, but without CV disease, who were treated with atorvastatin appeared to experience cardiovascular (CV) benefits similar to what has been observed in other populations, with a risk reduction of approximately one-third, according to a large, but prematurely terminated, trial in the
Sleep Myths Debunked
A panel of 10 sleep experts studied 20 common sleep myths and found little or no evidence in support of these beliefs.
Sleep issues are highly prevalent among US adults, but few admit to it or do anything to manage it.
Higher Comorbidities in Hidradenitis Suppurativa
JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.
